SPDR S&P Biotech ETF $XBI Stock Holdings Boosted by Royal Fund Management LLC

Royal Fund Management LLC boosted its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 13.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 162,850 shares of the exchange traded fund’s stock after purchasing an additional 19,137 shares during the period. SPDR S&P Biotech ETF makes up 2.0% of Royal Fund Management LLC’s portfolio, making the stock its 5th largest position. Royal Fund Management LLC’s holdings in SPDR S&P Biotech ETF were worth $20,814,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Management Partners LLC acquired a new stake in shares of SPDR S&P Biotech ETF in the 1st quarter worth $547,000. Banque Pictet & Cie SA boosted its holdings in shares of SPDR S&P Biotech ETF by 24.1% in the fourth quarter. Banque Pictet & Cie SA now owns 64,877 shares of the exchange traded fund’s stock valued at $7,910,000 after acquiring an additional 12,595 shares in the last quarter. Apella Capital LLC acquired a new position in shares of SPDR S&P Biotech ETF during the fourth quarter worth about $490,000. Mirae Asset Global Investments Co. Ltd. lifted its position in SPDR S&P Biotech ETF by 106.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,570 shares of the exchange traded fund’s stock valued at $3,240,000 after purchasing an additional 13,729 shares during the period. Finally, Keystone Investors PTE Ltd. acquired a new stake in SPDR S&P Biotech ETF in the fourth quarter valued at about $12,022,000.

SPDR S&P Biotech ETF Trading Down 1.2%

Shares of XBI opened at $147.91 on Thursday. SPDR S&P Biotech ETF has a twelve month low of $84.39 and a twelve month high of $165.71. The stock’s 50 day moving average is $145.48 and its two-hundred day moving average is $134.07. The firm has a market capitalization of $9.73 billion, a PE ratio of 11.47 and a beta of 0.82.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.